Table 1 Recipient and donor characteristics at time of transplantation in the discovery cohort (n = 77) and validation cohort (n = 32)
variable | Discovery cohort (n = 71) | Validation cohort (n = 32) | P |
|---|---|---|---|
Recipient characteristics | |||
Age, yr | 37.97 ± 11.49 | 37.28 ± 13.50 | 0.790 |
Gender | Â | Â | 0.333 |
 Male | 47(66.2%) | 18(56.3%) |  |
 Female | 24(33.8%) | 14(43.8%) |  |
BMI, kg/m2 | 21.44(18.67–24.36) | 20.10(18.11–23.53) | 0.259 |
Time on dialysis, m | 24(15–60) | 24(12–59.25) | 0.338 |
Dialysis, HD | 51(71.8%) | 19(59.4%) | 0.403 |
Immunosuppression regimen | Â | Â | 0.267 |
ATG,Tac, MMF, steroid | 15(21.1%) | 10(31.3%) | Â |
Basiliximab,Tac, MMF,steroid | 61(85.9%) | 24(75.0%) | Â |
Pre-Tx Creatinine,mg/dL | 12.05 ± 3.68 | 11.03 ± 3.43 | 0.189 |
history of hypertension | 61(85.9%) | 22(78.6%) | 0.177 |
history of diabetes mellitus | 3(4.2%) | 0(0%) | 0.238 |
Donor characteristics | Â | Â | Â |
Age, (yr) | 44(17–48) | 29.5(15–51.25) | 0.471 |
Gender | Â | Â | 0.545 |
 Male | 57(80.3%) | 24(75.0%) |  |
 Female | 14(19.7%) | 8(25.0%) |  |
BMI, kg/m2 | 22.86(18.81–24.22) | 23.75(18.11–24.80) | 0.526 |
Terminal Creatinine, mg/dL | 0.88(0.67–1.52) | 0.72(0.59–1.46) | 0.279 |
The donor type | Â | Â | 0.155 |
 DCD | 13(18.3%) | 4(12.5%) |  |
 DBD | 52(73.2%) | 28(87.5%) |  |
 DBCD | 6(8.5%) | 0(0%) |  |
Donor history of hypertension | 32(45.1%) | 10(31.3%) | 0.187 |
Donor history of diabetes mellitus | 16(22.5%) | 3(9.4%) | 0.111 |
Transplant characteristics | Â | Â | Â |
CIT,h | 9(7–11) | 9(7–9.375) | 0.309 |
HLA mismatches | 5(4–5) | 4(4–5) | 0.371 |